Dr. Ahmed Alfaraj


Chair of Clinical Oncology & Nuclear Medicine Department- Alexandria University Dr. Yousri A Rostom, MD, PhD. is a Professor of Clinical Oncology and Nuclear Medicine, Alexandria University.
He got his Master, MD and PhD degrees in Clinical Oncology and Nuclear Medicine from Alexandria University and obtained the Certificate of “Highly Specialized Training in Radiotherapy & Oncology” (Attestation de Formation Specialisée Approfondie de Oncologie Radiotherapique) October 1999, Claude Bernard University, Lyon, France.
He was granted Alexandria University Encouragement Award of Medical Sciences in 2007.
Prof. Yousri is a fellow of ‘Centre Hospitalier Lyon Sud’, Lyon, France, and a fellow of ‘Centre Antoine-la Cassagne Contre le Cancer’, Nice, France.
He was General Manager of One Day Service Centre (One Day Surgery& Outpatient Clinics Centre) in Alexandria University Hospitals, Faculty of Medicine, since 5th of January 2015 till 9th April, 2017.
Prof. Yousri is also a member of the American society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), Egyptian Cancer Society (EGS), and the Chair of Alexandria Oncology Foundation for Cancer Patient Advocacy. and many other social and medical societies.
He is also an active member of Rotary Club of Alexandria El Nozha since 2001.
Prof. Rostom is a reviewer of research papers for the Science and Technology Development Fund (STDF). His numerous professional publications focus on the fields of Clinical Oncology, New Radiation Therapy Techniques and Modalities, Hepatocellular Carcinoma Management and Cancer Informatics. He supervised many Master degree and Medical Doctorate thesis.
His current research group YOUNEV focuses on Healthcare Informatics.
He was recently granted the Certificate of Appreciation from Jamia Hamdard University in India for his valuable contribution during the webinar on “Digital Transformation: Facelifting Oncology” held on 21st of January, 2021.


Friday 3-5-2024 Day 1

Advanced HER2-positive/HER2-low breast cancer

Patient with brain metastasis and stable extracranial disease:  when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis:  T-DXd  vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd 
Role of repeated biopsies to guide ADCs in HER2-low BC

Moderator:  Shereef Elsamany


09:45 –10:30

Friday 3-5-2024 Day 1

Role of anthracyclines in early breast cancer

  • When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

    When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

Moderator:Dr. Meteeb Alfohaidi